WO1995012681A1 - Procede relatif a l'ir-95 - Google Patents

Procede relatif a l'ir-95 Download PDF

Info

Publication number
WO1995012681A1
WO1995012681A1 PCT/US1994/012701 US9412701W WO9512681A1 WO 1995012681 A1 WO1995012681 A1 WO 1995012681A1 US 9412701 W US9412701 W US 9412701W WO 9512681 A1 WO9512681 A1 WO 9512681A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
nucleic acid
vector
cell
administering
Prior art date
Application number
PCT/US1994/012701
Other languages
English (en)
Inventor
Stefano Iacobelli
Bahija Jallal
Clara Natoli
Jeff Powell
Axel Ullrich
Original Assignee
New York University
Universita Degli Studi 'g., D'annunzio'-Chieti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University, Universita Degli Studi 'g., D'annunzio'-Chieti filed Critical New York University
Priority to AU10498/95A priority Critical patent/AU1049895A/en
Priority to EP95901140A priority patent/EP0725828A1/fr
Publication of WO1995012681A1 publication Critical patent/WO1995012681A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the present invention relates generally to the fields of medicine and molecular and cellular biology and more specifically to the field of therapeutic antigens and antigen related products.
  • the present invention relates to the field of treating disorders, such as cancer, bacterial infection, parasitic infection, viral infection, autoimmune disorders, rheumatoid arthritis, allergy and organ transplant rejection.
  • tumor-specific antigens The insufficient immune response of tumor cells may be due to low expression of foreign ("tumor-specific") antigens.
  • tumor-specific antigens identification of tumor-specific antigens has been a major focus of tumor immunologists for decades.
  • Tumor cells also produce and secrete proteins which directly affect the host immune response to the tumor, either positively or negatively.
  • a tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor-associated tumor cells also produce and secrete proteins which directly affect the host immune response to the tumor, either positively or negatively.
  • IR-95 15 protein produced by 80% of breast cancers but not by normal breast tissue. Subsequent studies detected this protein, designated IR-95, in the sera of normal as well as tumor-bearing patients (Iacobelli et al., Breast Cancer Research and Treatment 11:19-30, 1993) .
  • IR-95 is a secreted glycoprotein that was originally identified in the culture supernatant of human breast cancer cells 1 and by cDNA cloning was identified as a member of the scavenger receptor cysteine-rich domain family of proteins 2,3 . Although IR-95 is found in the serum
  • Mac-2-BP was shown to inhibit the proli ⁇ ferative response of peripheral blood mononuclear cells stimulated with the T-cell mitogen PHA, and this inhibi ⁇ tion was attributed to competitive binding and neutraliza ⁇ tion of the mitogen, rather than to a direct effect of Mac-2-BP on the responding cell population.
  • IR-95 has been shown to enhance the in vi tro genera ⁇ tion of cytotoxic effector cells (NK and LAK) from PBMC of apparently healthy donors, and to enhance IL-2 production by peripheral blood mononuclear cells (PBMC) stimulated with suboptimal doses of Concanavalin A (Ullrich et al. , J. Biol . Chem. 269:18401-18407, 1994), incorporated herein by reference in its entirety, including any drawings.
  • PBMC peripheral blood mononuclear cells
  • T-cell activation an important step in many immune responses, requires crosslinking of the T-cell receptor:CD3 complex by HLA-peptide complexes on the surface of antigen presenting cells.
  • HLA-peptide complexes presenta ⁇ tion of HLA-peptide complexes in the absence of certain costimulatory signals results in T-cell anergy rather than activation (Johnson and Jenkins, Jini ⁇ unologic Res . 12:48- 64, 1993) .
  • B7 the ligand for the T-cell molecule CD28
  • CD28 the ligand for the T-cell molecule CD28
  • Antigen presentation by B7-negative APC results in T-cell anergy, while the introduction of B7 into these deficient APC restores their ability to activate T-cells following antigen presentation (Gimmi et al. , Proc. Natl . Acad. Sci . 90:6586-90, 1993) .
  • Soluble mediators are also important costimulatory signals in T-cell activation.
  • IL-1 supports the antigen-driven activation of T-cells (Rotteveel et al., Cellular Immunol . 138:245-50, 1991) , and the production of lymphokines such as IL-9 (Schmitt et al. , J. Immunol . 147:3848-54, 1991) .
  • IL-6 exhibits a number of effects on T-cell activation, including stimulation of thymocyte proliferation, enhancement of cytotoxic T-cell differentiation in mixed lymphocyte reactions, and T-cell activation in conjunction with TCR crosslinking or mitogen stimulation (See Van Snick, Ann . Rev. Immunol .
  • tumor cells are non-immuno ⁇ genic and lethal when implanted into mice.
  • B7-negative tumor cells are non-immuno ⁇ genic and lethal when implanted into mice.
  • the tumor cells become immunogenic, eliciting an immune response that recognizes not only the B7-positive immunogenic tumor, but also the B7-negative nonimmunogenic parental tumor (Baskar et al. , Proc . Natl . Acad. Sci . USA 90:5687-5690, 1993; Fenton et al., AACR Symposium on Molecular Approaches to Cancer Immunotherapy. Page B-l, 1993) .
  • IL-2 (Bubenik, Intl J. Oncology 2:1049-1052, 1993; Tsai et al. , JNCI 85:546- 53, 1993; Porgador et al., J. Immuno therapy 14:191-201, 1993)
  • IL-4 (Yu et al. , Cancer Res . 53:3125-8, 1993; Hunt et al., J. Immuno therapy 14:314-21, 1993)
  • GM-CSF (Dranoff et al., Proc. Natl . Acad. Sci .
  • cytokines when administered systemically or locally, can lead to successful immune recognition of the tumor, and mobilization of an effective immune response (Sivanandham et al. , Annals of Plastic Surgery 28:114-118, 1992; Dipierro et al. , Medical Oncology and Pharmaco- therapy 10:53-59, 1993) .
  • Recent advances in gene transfer technology have allowed the insertion of genes encoding the cytokines of interest into non-immunogenic tumor cells.
  • Such cytokine-engineered tumor cells elicit a strong tumor-specific immune response that is capable of recognizing and eradicating the parental, non-immunogenic tumor cells (Dranoff et al., Proc. Natl . Acad. Sci . USA 90:3539-43, 1993; Patel et al. , J. Immunotherapy 14:310-3, 1993; Bubenik, Intl J. Oncology 2 :1049-1052, 1993).
  • the present invention relates to therapeutic uses of IR-95, for example its use in reducing the volume of a tumor or in decreasing the growth rate of cells in the tumor, preferably in vivo .
  • IR-95 increases the production of cytokines IL-1 and IL-6 by human peripheral blood lymphocytes, and acts synergistically with Concanavalin A (ConA, a potent T-cell mitogen) to increase the production of IL-2. It has also been discovered that the development of tumors in nude mice is decreased (slower tumor growth and decreased tumor volume) when the mice are implanted with cells that express IR-95.
  • the invention relates to IR-95 gene transfer and gene therapy products and methods.
  • the invention features a pharmaceutical composition having a therapeutically effective amount of IR-95 and a physiologically acceptable carrier or diluent.
  • agents of this invention have a “therapeutic effect” which gener- ally refers to either: (a) the inhibition to some extent of growth of cells causing or contributing to a particular disorder; or (b) relief of symptoms or the inhibition to some extent of the causes or contributors of such a dis ⁇ order.
  • the doses of IR-95 and antagonist(s) thereof which are useful as a treatment are “therapeutically effective amounts”, which as used herein, means an amount of the protein, fragment or antagonist thereof, which produces the desired therapeutic effect. This amount can be routinely determined by one of skill in the art and will vary depending upon several factors such as the particular illness from which the patient suffers and the severity thereof, as well as the patient's height, weight, sex, age, and medical history.
  • a "therapeutic effect” relieves to some extent one or more of the symptoms of the disorder.
  • a therapeutic effect refers to one or more or the following: 1) reduction in tumor size; 2) inhibition (i.e. , slowing to some extent, preferably stopping) of tumor metastasis; 3) inhibition, to some extent, of tumor growth; and/or 4) relieving to some extent one more or the symptoms associated with the disorder.
  • a therapeutic effect refers to the ability to remove or reduce one or more symptoms associated with the disorder and includes the ability to inhibit the growth and/or survival of a foreign organism. Other such symptoms are well known to members of the medical community.
  • IR-95 is meant the 90K-tumor associated antigen described in PCT patent application No. WO 93/16181, pub- lished August 19, 1993, and the functional derivatives of IR-95 described herein.
  • the term IR-95 is meant to refer to the full-length protein and any active fragments thereof. Fragments which are active may be identified in vi tro or by testing for the ability to affect tumor growth in nude mice.
  • Physiologically acceptable carriers and diluents are known in the art and are described in detail herein.
  • the carrier or diluent is not a material that is commonly used to buffer the pH of a solution, such as Tris buffer.
  • the therapeutically effective amount is preferably between about 5 to about 5,000 mg/dose/week/patient and more preferably between 50 and 500 mg/dose/week/patient.
  • the invention features the use of IR-95 in the manufacture of a medicant for the treatment of a disorder, preferably cancer, a bacterial infection or a viral infection.
  • disorder is meant a state in an organism (e.g.. a human) which is recognized as abnormal by members of the medical community.
  • the disorder may be an infection by a foreign organism or uncontrolled cell proliferation (e.g. , tumor growth) .
  • disorders to be treated by the present invention include cancers (e.g. , breast or ovarian cancer) , immune disorders (e.g. , autoimmune disorders) and infections (e.g.. bacterial or viral infections, including retroviral infections such as HIV) .
  • cancers e.g. , breast or ovarian cancer
  • immune disorders e.g. , autoimmune disorders
  • infections e.g.. bacterial or viral infections, including retroviral infections such as HIV
  • cytokines for example IR-95
  • the invention features a method of treating a disorder.
  • the method involves administering a therapeutically effective amount of IR-95 to an organism in need of such treatment.
  • the disorder is either cancer, a bacterial infection, a para- sitic infection, or a viral infection
  • the therapeu ⁇ tically effective amount is between about 5 to about 5,000 mg/dose/wk/patient, more preferably between 50 and 500 mg/dose/wk/patient.
  • organism any living creature.
  • the term includes mammals, and specifically humans.
  • Preferred organisms include mice, as the ability to treat or diag ⁇ nose mice is often predictive of the ability to function in other organisms such as humans.
  • Organisms in need of treatment may be identified using routine diagnostic methodologies, for example by detecting the symptoms characteristic of the particular disorder to be treated (e.g. , cancer, bacterial infection, or viral infection) .
  • Patients in need of treatment may also be identified by detecting the level of IR-95 in the organism as an indication of need for treatment.
  • administering a therapeu ⁇ tically effective amount of IR-95 to an organism involves implanting the organism with cells capable of expressing IR-95; the volume of a tumor in the organism is reduced or the growth rate of cells in the tumor is decreased; cytokine (e.g. , IL-1 or IL-6) production is increased; and the IR-95 is present a concentration of 10 mg/ml to 20 mg/ml.
  • cytokine e.g. , IL-1 or IL-6
  • the invention features a pharmaceu ⁇ tical composition having a therapeutically effective amount of an IR-95 antagonist and a physiologically acceptable carrier or diluent.
  • an IR-95 antagonist is meant any agent that decreases the effect of IR-95 in vivo or in vi tro .
  • IR-95 antagonists include antisense and ribozyme agents as described herein.
  • the invention features the use of an IR-95 antagonist in the manufacture of a medicant for the treatment of an autoimmune disorder, rhuematoid arthritis, allergy, or organ transplant rejection.
  • autoimmune disorder any disease, disease state or pathology mediated in whole or in part by cells of the immune system causing damage to or compro ⁇ mising function of tissues or cells present endogenously in an organism. This may include pathologies mediated by T lymphocytes causing damage to body tissues or patholo ⁇ gies mediated by antibodies secreted extracellularly from cells of the immune system.
  • autoimmune dis ⁇ orders to be treated by the present invention include Addison's disease, autoimmune hemolytic anemia, Crohne's disease, Goodpasture's syndrome, Graves' disease, Hashimoto's thyroiditis, idiopathic thrombocytopenic purpura, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, perni ⁇ cious anemia, poststreptococcal glomrulonephritis, psoriasis, rheumatoid arthritis, scleroderma, Sj ⁇ gren's syndrome, spontaneous infertility, and systemic lupus erythematosus.
  • the invention features a method of suppressing an immune response.
  • the method involves administering a therapeutically effective amount of a IR-95 antagonist to an organism in need of such treatment.
  • the patient is suffering from an autoimmune disorder, rheumatoid arthritis, allergy, or organ transplant rejection, and the therapeutically effective amount is between about 5 to about 5,000 mg/dose/wk/patient, more preferably between 50 and 500 mg/dose/wk/patient.
  • suppressing is meant that the immune response is decreased or eliminated. Suppressing an immune response may preferably remove an abnormal level of immune response that is associated with a disorder and/or cause the- level of immune response to approach a level associated with normal or healthy individuals.
  • immuno response is meant the response of the whole or part of an immune system of an organism, i.e.. cellular and humoral systems in vivo or in vi tro . In preferred embodiments, the immune response is either the proliferation or differentiation of a cell selected from the group that consists of T-lymphocytes, B-lymphocytes, natural killer cells, monocytes and granulocytes. An immune response may thus be measured using techniques well known in the art.
  • a IR-95 antagonist can be administered.
  • the appropriate doses of the antag- onist can be routinely determined by one of skill in the art as described herein.
  • the antagonist(s) of IR-95 is preferably provided at a dose of between about 5 to about 5000 mg/dose/week/patient. More specifically, one preferable dose range is from 50 to 500 mg/dose/week/ patient.
  • the invention features a phamaceu- tical composition
  • a therapeutically effective amount of nucleic acid encoding IR-95 and a physiologi ⁇ cally acceptable carrier or diluent is described in PCT Application No WO 93/16181, published August 19, 1993.
  • the invention also provides the use of nucleic acid encoding IR-95 in the manufacture of a medicant for the treatment of cancer, a bacterial infection, a parasitic infection or a viral infection.
  • the invention features a phar ⁇ maceutical composition
  • a phar ⁇ maceutical composition comprising cells capable of expressing IR-95 and a physiologically acceptable carrier or diluent.
  • the invention also features the use of cells capable of expressing IR-95 in the manufacture of a medicant for the treatment of cancer, a bacterial infection, a para ⁇ sitic infection or a viral infection.
  • Also provided is a method of treating a disorder comprising implanting an organism in need of treatment with cells capable of expressing IR-95.
  • the volume of a tumor in said organism is reduced or the growth rate of cells in said tumor is decreased.
  • cytokine for example IL-1 or IL-6
  • IR-95 is present in a concentration of 10 mg/ml to 20 mg/ml.
  • the invention provides a vector in a liposome, said vector comprising nucleic acid encoding IR-95 and being adapted to cause expression of said IR-95.
  • vector is meant a nucleic acid, e. g. , DNA derived from a plasmid, cosmid, phagemid or bacteriophage, into which fragments of nucleic acid may be inserted or cloned.
  • the vector can contain one or more unique restriction sites for this purpose, and may be capable of autonomous replication in a defined host or organism such that the cloned sequence is reproduced.
  • the vector mole ⁇ cule can confer some well-defined phenotype on the host organism which is either selectable or readily detected.
  • Some components of a vector may be a DNA molecule further incorporating a DNA sequence encoding a therapeutic or desired product, and regulatory elements for transcrip ⁇ tion, translation, RNA stability and replication.
  • a viral vector in this sense is one that contains a portion of a viral genome, e . g. , a packaging signal, and is not merely DNA or a located gene within a viral article.
  • expression of said IR-95 results in the production of functional IR-95 and the vector comprises a retroviral vector.
  • a vector comprising nucleic acid encodes IR-95.
  • the IR-95 vector is adapted to cause expression of a IR-95.
  • Expression includes the efficient transcription of an inserted gene or nucleic acid sequence within the vector.
  • Expression products may be proteins, polypeptides or RNA.
  • expression of IR-95 is meant that a complete or functional partial IR-95 protein is produced from the vector containing the nucleic acid encoding IR-95.
  • transfected cell line containing a vector comprising nucleic acid encoding IR-95.
  • the IR-95 is expressed as a secreted protein.
  • a cell may be co-transfected with a vector containing a selectable marker. This selectable marker is used to select those cells which have become transfected. Types of selectable markers which may be used are well known to those of ordinary skill in the art.
  • a transfected cell containing a IR-95 vector may only be transiently transfected, resulting in transient expression of a IR-95.
  • transfected refers to a cell having undergone the process of introduction of nucleic acid or a nucleic acid vector into a cell.
  • stable refers to the introduction of a gene into the chromosome of the targeted cell where it integrates and becomes a permanent component of the genetic material in that cell.
  • An episomal trans- fection is a variant of stable transfection in which the introduced gene is not incorporated in the host cell chromosomes but rather is replicated as an extrachromo- somal element. This can lead to apparently stable transfection of the characteristics of a cell.
  • transient as used herein relates to the introduction of a gene into a cell to express a IR-95, where the introduced gene is not integrated into the host cell genome and is accordingly eliminated from the cell over a period of time.
  • Transient expression relates to the expression of a gene product during a period of transient transfection.
  • the invention also provides a transformed cell line containing a vector comprising nucleic acid encoding IR-95.
  • a cell stably transformed with a IR-95 vector may be co-transformed with a vector containing a selectable marker. This selectable marker is used to select those cells which have become transformed. Types of selectable markers which may be used are well known to those of ordinary skill in the art.
  • transformed refers to a process or mechanism of inducing transient or permanent changes in the characteristics (expressed phenotype) of a cell by the mechanism of gene transfer whereby DNA or RNA is introduced into a cell in a form where it expresses a specific gene product or alters the expression or effect of endogenous gene products.
  • the invention features a transgenic non-human animal containing IR-95.
  • An additional preferred embodiment provides for a transgenic animal containing a IR-95 vector.
  • the transgenic animal is a mammal, for example a mouse.
  • transgenic animal an animal whose genome contains an additional copy or copies of the gene from the same species or it contains the gene or genes of another species, such as a gene encoding a IR-95 intro ⁇ quizin and as known in the art.
  • the transgenic animal can include the resulting animal in which the vector has been inserted into the embryo from which the animal developed or any progeny of that animal.
  • progeny includes direct progeny of the transgenic animal as well as any progeny of succeeding progeny.
  • progeny includes direct progeny of the transgenic animal as well as any progeny of succeeding progeny.
  • progeny includes direct progeny of the transgenic animal as well as any progeny of succeeding progeny.
  • the invention features a method for introducing a continuous supply of IR-95 into an animal, comprising the step of administering an effective amount of a vector of the present invention into said animal.
  • the invention also provides a method for introducing a continuous supply of IR-95 into a tissue culture, compris ⁇ ing the step of administering an effective amount of a vector of the present invention into said tissue culture.
  • a method of introducing a continuous supply of IR-95 into an animal or a tissue culture by administering an effective amount of a vector is provided.
  • IR-95 is consti- tutively expressed without the need for the addition of an exogenously administered activating compound to initiate expression.
  • the term "effective amount” means an amount suffi ⁇ cient to give expression of some amount of IR-95 in the muscle or tissue culture.
  • the invention features a method of screening compounds for their pharmacological effects on an immune response comprising the steps of administering a compound to a transgenic animal expressing IR-95 and measuring said immune response in said trans ⁇ genic animal.
  • Also provided is a method of administering a nucleic acid sequence encoding a IR-95 to an animal comprising the steps of removing cells from said animal, transfecting said cells with said IR-95 nucleic acid sequence, and reimplanting said transfected cells into said animal.
  • This transgenic animal is useful in screening compounds for their pharmacological effects on an immune response comprising the steps of administering compounds to the transgenic animal and measuring the immune response in the transgenic animal.
  • an in vivo method of administering a nucleic acid sequence is provided, as described below.
  • naked DNA may be administered.
  • naked DNA means substantially pure DNA which is not associated with protein, lipid, carbohydrate or contained within a cell or an artificial delivery system such as a liposome.
  • a tissue or cell may also be transduced with a IR-95 vector.
  • transfected or transfection refers to the process of introducing a recombinant virus into a cell by infecting the cell with the virus particle.
  • the virus may be administered substantially simultane ⁇ ously, i.e., the IR-95 nucleic acid sequence and the virus may administered in the same composition or that the administration of one may follow the other by about up to one hour.
  • a method of administering IR-95 nucleic acid sequence, through cell surface receptor mediated endocytosis is provided. That is, the biological process whereby cell surface receptors which have bound a ligand cluster together on the cell surface followed by invagination of the cell membrane containing the clustered receptors and formation of an intercellular vesicle containing the receptor ligand complexes.
  • a "cell surface receptor” is a specific chemical grouping on the surface of a cell to which a ligand can attach.
  • Cell surface receptors which may be used in the present invention include the folate receptor, the biotin receptor, the lipoic acid receptor, the low density lipo- protein receptor, the asialoglycoprotein receptor, IgG antigenic sites, insulin-like growth factor type II/cation-independent mannose-6-phosphate receptor, calcitonin gene-related peptide receptor, insulin-like growth factor I receptor, nicotinic acetylcholine receptor, hepatocyte growth factor receptor, endothelin receptor, bile acid receptor.
  • Such com ⁇ plexes may include lipids, polylysine, viral particles, ligands for specific cell-surface receptors or nuclear proteins.
  • DNA transporter refers to a molecular complex which is capable of non-covalently binding to DNA and efficiently transporting the DNA through the cell membrane. Although not necessary, it is preferable that the transporter also transport the DNA through the nuclear membrane.
  • a two-component system of administering a IR-95 nucleic acid sequence is provided.
  • two-component system means a system utilizing a packaging cell which produces a viral vector.
  • a partial hepatectomy may be performed prior to administration of the packaging cell.
  • hepatectomy or "partial hepatectomy” is used as is commonly understood in the art.
  • a retroviral vector containing a modified retroviral envelope glyco- protein is provided.
  • retroviral envelope glyco ⁇ protein is used as is commonly understood in the art.
  • the invention features a method of treating a disorder comprising the steps of: (a) inserting an expression vector comprising nucleic acid encoding IR-95 into a cell;
  • the invention also features a method of administering a IR-95 nucleic acid sequence utilizing an in vivo approach comprising the steps of administering directly to an animal said IR-95 nucleic acid sequence selected from the group of methods of administration consisting of intravenous injection, intramuscular injection, or by catheterization and direct delivery of said IR-95 nucleic acid sequence via the blood vessels supplying a target organ.
  • the target organ is selected from the group consisting of heart, skeletal muscle, adi ⁇ pose tissues, spleen, lung, brain, kidney, testis, adrenal or small intestine; the IR-95 nucleic acid sequence is administered as naked DNA; the IR-95 nucleic acid sequence is contained in a viral vector such as papovaviruses, adenovirus, vaccinia virus, adeno-associated virus, herpesviruses and retroviruses of avian, murine or human origin.
  • a viral vector such as papovaviruses, adenovirus, vaccinia virus, adeno-associated virus, herpesviruses and retroviruses of avian, murine or human origin.
  • the invention features a method of administering a IR-95 nucleic acid sequence in a two-component system comprising the steps of administering a packaging cell, wherein said packaging cell produces a viral vector.
  • the packaging cell is administered to cells in vi tro .
  • Also featured is a method of administering a IR-95 nucleic acid sequence comprising the step of administering to an animal an adenovirus vector, wherein an El region of said adenovirus vector is replaced with said IR-95 nucleic
  • the invention provides a gene therapy produce comprising a therapeutically effective amount of nucleic acid encoding IR-95 and a means for administering said nucleic acid.
  • the means for admini ⁇ stering may be a needle for microinjection, a gene gun, a vector, a device for electroporation, a liposome, a small projectile used on particle bondediment, a protein used in receptor mediated endocytosis, a DNA transporter, or any other means for providing such nucleic acid.
  • the present invention is thus based on the surprising discovery that administration of nucleic acid encoding IR-95 is capable of producing a therapeutic effect when administered to an organism.
  • the invention provides a gene transfer method for administering nucleic acid encoding IR-95 to an organism.
  • the invention provides a gene therapy method for administering a therapeutically effective amount of nucleic acid encoding IR-95 to an organism in need of such treatment.
  • IR-95 gene therapy is effective in vivo.
  • those skilled in the art will now recognize that effective IR-95 gene therapy may take various forms and thus, many modifications of the exem- plary techniques are encompassed by the present invention.
  • kits useful for carrying out the methods described herein Such kits would all share the common features of containing nucleic acid encoding, IR-95, and one or more components required to administer the gene therapy produce.
  • the kits may also include other components such as the vectors useful in expressing IR-95, a needle or syringe useful for microinjection, transfected or transformed cells, an I.V., a catheter, a packaging cell, materials useful for transfection, electorporation, lipofection, particle bombardment, or coupling of chemic- ally modified proteins.
  • kits may contain various combinations, of the above components.
  • CM conditioned medium
  • GM-CSF granulocyte- macrophage colony-stimulating factor
  • LAK lymphokine- activated killer cell
  • MTT 3- [4, 5-dimethylthiazol-2-yl] - 2, 5-diphenyltetrazolium bromide.
  • Figure 1 shows inhibition of tumor growth in nude mice.
  • 2 x IO 6 cells were subcutaneously implanted above the right hind leg in nude mice.
  • Each experimental group consisted of 8 animals, which were independently injected.
  • the control groups for each experiment represent parental cells before or after pLXSN virus infection. Data points represent average tumor volumes of all experimental animals in one group. P. Values were calculated by Student's t-test comparison of mean tumor volumes to that of the appropri- ate control group.
  • Figure la shows formation of solid tumors by virus-infected MM5 cells.
  • D tumor growth in control animals implanted with MM5 cells only.
  • Figure le shows the effect of IR-95 expression on tumor formation by SF7763t cells.
  • IR-95-expressing cell lines were established as described in Example 9. Parental cells and retrovirus- infected cells were trypsinized and washed several times in phosphate buffered saline (PBS) . For implantation, cells were resuspended in 100 ⁇ l of PBS and implanted subcutaneously above the left or right hind leg of four- to-eight-week-old nude mice. Starting at the time when developing tumors were first visible, measurements of tumor volumes were done at regular intervals twice a week. The animals were sacrificed when the tumor reached a volume greater than 2500 mm 3 . The inhibitory effect of IR-95 production on tumor growth was calculated by comparison of the average tumor volume produced by IR-95- secreting cells in 8 animals with the volume of tumors from animals of the respective control group.
  • PBS phosphate buffered saline
  • the human glioblastoma SF763t cell line was infected with a photropic viruses which were obtained after infec- tion of PA317 cells with ecotropic virus.
  • Cells (10 7 /mouse) were subcutaneously implanted in nude mice as described above. Description of the Preferred Embodiments
  • the present invention provides therapeutic methods relating to IR-95.
  • Methods for isolating and purifying the antigen, for producing monoclonal or polyclonal antibodies, for sequencing the protein, for producing probes, and methods for modifying and expressing the disclosed nucleotide and amino acid sequences are described in PCT Application Publication WO 93/16181, published August 19, 1993.
  • the purified protein and antibodies thereto as well as its genetic sequences are useful in therapeutic methods.
  • IR-95 and antagonists thereof are useful as therapeutic agents for cancer, including breast, ovarian and other malignancies, viral infection, including HIV, bacterial infection, parasitic infection, inflamma ⁇ tion, autoimmune disease, aging, and different physio- pathological conditions which are characterized by a variable degree of immune deficit associated with immune activation or elevated serum IR-95 levels.
  • viral infection including HIV, bacterial infection, parasitic infection, inflamma ⁇ tion, autoimmune disease, aging, and different physio- pathological conditions which are characterized by a variable degree of immune deficit associated with immune activation or elevated serum IR-95 levels.
  • PBMC peripheral blood mononuclear cells
  • IL-1 and IL-6 production were induced by IR-95 alone, indicating that the actual target of activation was the accessory cell, not the T-cell.
  • T-cells enriched by passage over nylon wool failed to respond to ConA alone or in combination with IR-95, while CD14- enriched cells produced IL-1 and IL-6 when stimulated with IR-95 alone, regardless of the presence or absence of the T-cell mitogen ConA.
  • CD14+ accessory cells which produce IL-1 and IL-6 in response to IR-95, and that IR-95 acts upon accessory cells independently of ConA.
  • IR-95 was also found to increase the expression on monocytes of ICAM-1, an important adhesion molecule involved in costimulation of T-cells.
  • IR-95 alone i.e. , without ConA
  • IL-1 and IL-6 were sufficient to induce production of IL-1 and IL-6 by unfractionated PBMC or by CD14-enriched PBMC.
  • expression of ICAM-1 was increased on a human monocytic cell line cultured with purified IR-95 in the absence of any other stimulus. This IR-95-induced upregulation of ICAM-1 expression was accompanied by an increased accessory function of the monocytes, as deter- mined by their ability to support ConA-induced activation of peripheral blood T-cells.
  • IR-95 thus activates accessory cells, resulting in the secretion of cytokines, activation of helper T-cells and effector cells such as NK and LAK, and expression of adhesion molecules, which in turn act as costimulatory signals for T-cell activation.
  • the activated T-cells then produce cytokines such as IL-2, which lead to a more vigorous cell-mediated immune response to tumor cells and virus-infected cells.
  • IR-95 may be used as an immunotherapeutic reagent for diseases such as cancer and viral infection, due to its ability to enhance cell- mediated immune responses.
  • IR-95 ConA-induced T-cell activation may be due to its ability to directly activate accessory cell secretion of IL-1 and IL-6, both of which are involved in T-cell activation. Therefore, we examined the effect of IR-95 on adhesion molecule expression and accessory function of a human monocytic cell line, THP-1. In agreement with the experiments with CD14+ PBMC, we found that IR-95 had a direct positive effect on THP-1 cells, evidenced as an increase in ICAM-1 expression following an overnight culture with IR-95.
  • IR-95 upregulate ICAM-1 expression did not only affect the ability of the THP-1 cells to support T- cell activation: IR-95-pulsed THP-1 cells caused a 2-fold increase in T-cell proliferation compared to non-pulsed cells.
  • the activated T-cells may then produce lymphokines (in addition to IL-2) which act in a feedback loop to increase accessory cell activation and cytokine secretion; this mechanism could explain why in some experiments, the addition of both IR-95 and ConA appeared to synergistic- ally increase the levels of cytokines produced.
  • IR-95 appears to be a soluble costimulatory molecule, which acts at the level of the accessory cell, indirectly supporting T-cell activation. Secretion of IR-95 by tumor cells or normal cells (Ullrich et al. , J. Biol . Chem. 269:18401-18407, 1994) presumably triggers the first step in a cascade which ultimately results in enhanced cell- mediated immunity. While the current results indicate that IR-95 induces cytokine production by accessory cells, the effect of IR-95 on expression of adhesion molecules may be just as important in ultimate T-cell activation. Indeed, we present evidence that incubation with IR-95 increases expression of ICAM-1 (also known as CD54) on a human monocytic cell line, concomitant with an increase in the ability of the THP-1 cells to support T-cell activation.
  • ICAM-1 also known as CD54
  • IR- 95 is capable of altering tumor cell growth in vivo .
  • Clones which express high amounts of human IR-95 were, developed from murine 6378 cells (derived from mouse mammary gland carcinoma) and used for tumor growth experi ⁇ ments.
  • female nude mice, 4 to 5 weeks old were divided into 4 groups of 4 individuals.
  • Each individual in groups 1, 2 and 3 was subcutaneously implanted with a clone of murine 6378 cells which produced human IR-95 (2 x IO 6 cells / mouse) .
  • the animals in group 4 were implanted with 6378 cells which do not produce human IR-95.
  • the tumor volume in each animal was measured twice a week and the tumor growth curve determined.
  • mice implanted with the 6378 cells expressing human IR-95 showed significantly slower tumor growth than mice implanted with control cells. Twenty-three days post implantation, the tumor volume in mice implanted with the cells expressing IR-95 was reduced by 40% (group 1) , and 70% (group 2, 3) as compared to the control group.
  • IR-95-encoding cDNA has now been cloned four times. While we 2 and Koths et al. 3 identified human IR-95 as a tumor- associated secreted antigen or the Mac-2-BP, respectively, the putative mouse homologue of IR-95 was independently isolated as either cyclophilin C-associated protein (CyCAP) 16 or murine adherent macrophage (MAMA) protein 17 . The common denominator of the four independent investiga ⁇ tions that converged on the discovery of the IR-95 (IR-95/ Mac-2-BP/CyCAP/MAMA) protein appears to be a function in the body's immune surveillance and defense against cancer cells and likely other pathogenic agents.
  • CyCAP cyclophilin C-associated protein
  • MAMA murine adherent macrophage
  • IR-95 is likely to be involved in shielding the body from invasion by pathogens such as bacteria and parasites.
  • pathogens such as bacteria and parasites.
  • IR-95 or its genetic sequences will be useful in therapy as an immunoregulatory agent.
  • patients who suffer from a particular cancer which does not induce over expression of IR-95 may be treated by infusion with IR-95.
  • those patients with cancers that generate elevated levels of IR-95 in their serum, may be supplied additional IR-95 by infusion.
  • IR-95 or its genetic sequences will also be useful in gene therapy (reviewed in Miller, Nature 357:455-460, (1992) . Miller states that advances have resulted in practical approaches to human gene therapy that have demonstrated positive initial results.
  • An in vivo model of gene therapy for human severe combined immunodeficiency is described in Ferrari, et al., Science 251:1363-1366,
  • an expression vector containing the IR-95 coding sequence is inserted into cells, the cells are grown in vi tro and then infused in large numbers into patients.
  • a DNA segment containing a promoter of choice (for example a strong promoter) is transferred into cells containing an endogenous IR-95 in such a manner that the promoter segment enhances expression of the endogenous IR- 95 gene (for example, the promoter segment is transferred to the cell such that it becomes directly linked to the endogenous IR-95 gene) .
  • IR-95 to induce cytokine production and adhesion molecule expression by lymphocytes makes it useful for gene therapy of tumors.
  • Tumor cells which do not express IR-95 may be engineered to do so, thereby at least partially restoring the immunogenicity of the tumor cells.
  • Local production of IR-95 at the site of the tumor could lead to activation of infiltrating monocytes and macrophages.
  • Increased secretion of pro-inflammatory cytokines such as IL-1 and IL-6 could result in a greater degree of infiltrating, activated Th cells and effector cells (CTL, NK/LAK) .
  • Increased expression of adhesion molecules by accessory cells could lead to more vigorous T-cell activation in si tu .
  • the engineered expres ⁇ sion of IR-95 in non-expressing tumor cell lines inhibits the ability of the cells to grow as xenografts in athymic mice.
  • the gene therapy may involve the use of an adenovirus containing IR-95 cDNA targeted to a tumor, systemic IR-95 increase by implantation of engineered cells, injection with IR-95 virus, or injection of naked IR-95 DNA into appropriate tissues.
  • Target cell populations e.g. haematopoietic, muscle, or immune cells
  • an abnormal immune response leading to a condition may be decreased, inhi ⁇ bited, or reversed.
  • Deletion or missense mutants of IR- 95, that retain the ability to interact with other compo ⁇ nents of the immune system but cannot participate in normal immune response function may be used to inhibit an abnormal, deleterious immune response.
  • Expression vectors derived from viruses such as retroviruses, vaccinia virus, adenovirus, adeno-associated virus, herpes viruses, several RNA viruses, or bovine papilloma virus, may be used for delivery of nucleotide sequences (e.g.. cDNA) encoding recombinant IR-95 protein into the targeted cell population (e.g.. tumor cells) .
  • nucleotide sequences e.g.. cDNA
  • Methods which are well known to those skilled in the art can be used to construct recombinant viral vectors con ⁇ taining coding sequences. See, for example, the techniques described in Maniatis et al. , Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, N.Y.
  • nucleic acid molecules encoding protein sequences can be used as naked DNA or in recon- stituted system e.g. , liposomes or other lipid systems for delivery to target cells (See e.g.. Feigner et al., Nature 337:387-8, 1989).
  • recon- stituted system e.g. , liposomes or other lipid systems for delivery to target cells.
  • Feigner et al. Nature 337:387-8, 1989.
  • gene transfer can be performed by simply injecting minute amounts of DNA into the nucleus of a cell, through a process of microinjection.
  • Capecchi MR Cell 22:479-88 (1980) .
  • genes Once recombinant genes are introduced into a cell, they can be recognized by the cells normal mechanisms for transcription and translation, and a gene product will be expressed.
  • Other methods have also been attempted for introducing DNA into larger numbers of cells. These methods include: transfection, wherein DNA is precipitated with CaP0 4 and taken into cells by pinocytosis (Chen C. and Okayama H, Mol. Cell Biol. 7:2745-52 (1987)); electroporation, wherein cells are exposed to large voltage pulses to introduce holes into the membrane (Chu G.
  • adenovirus proteins are capable of destabilizing endosomes and enhancing the uptake of DNA into cells.
  • the admixture of adenovirus to solutions containing DNA complexes, or the binding of DNA to polylysine covalently attached to adenovirus using protein crosslinking agents substantially improves the uptake and expression of the recombinant gene.
  • gene transfer means the process of introducing a foreign nucleic acid molecule into a cell. Gene transfer is commonly performed to enable the expres ⁇ sion of a particular product encoded by the gene.
  • the product may include a protein, polypeptide, anti-sense DNA or RNA, or enzymatically active RNA.
  • Gene transfer can be performed in cultured cells or by direct administration into animals. Generally gene transfer involves the process of nucleic acid contact with a target cell by non ⁇ specific or receptor mediated interactions, uptake of nucleic acid into the cell through the membrane or by endocytosis, and release of nucleic acid into the cyto ⁇ plasm from the plasma membrane or endosome. Expression may require, in addition, movement of the nucleic acid into the nucleus of the cell and binding to appropriate nuclear factors for transcription.
  • gene therapy is a form of gene transfer and is included within the definition of gene transfer as used herein and specifically refers to gene transfer to express a therapeutic product from a cell in vivo or in vi tro .
  • Gene transfer can be performed ex vivo on cells which are then transplanted into a patient, or can be performed by direct administration of the nucleic acid or nucleic acid-protein complex into the patient.
  • a vector having nucleic acid sequences encoding IR-95 is provided in which the nucleic acid sequence is expressed only in specific tissue.
  • Methods of achieving tissue-specific gene expres ⁇ sion as set forth in International Publication No. WO 93/09236, filed November 3, 1992 and published May 13, 1993.
  • nucleic acid sequence contained in the vector may include additions, deletions or modifications to some or all of the sequence of the nucleic acid, as defined above.
  • Gene replacement means supplying a nucleic acid sequence which is capable of being expressed in vivo in an animal and thereby providing or augmenting the function of an endogenous gene which is missing or defective in the animal.
  • antisense or ribozyme approaches may be used to regulate an immune response. Included in the scope of the invention are oligoribonucleotides, including anti- sense RNA and DNA molecules and ribozymes that function to inhibit translation of IR-95. Anti-sense RNA and DNA molecules act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation. With respect to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site, e.g. , between -10 and +10 regions of the relevant nucleotide sequence, are preferred.
  • Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA.
  • the mechanism of ribozyme action involves sequence specific interaction of the ribozyme molecule to complementary target RNA, fol ⁇ lowed by a endonucleolytic cleavage.
  • engineered hammerhead or other motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of RNA sequences encod- ing protein complex components.
  • ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted struc ⁇ tural features, such as secondary structure, that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with comple ⁇ mentary oligonucleotides, using ribonuclease protection assays. See, Draper PCT WO 93/23569.
  • RNA molecules may be generated by in vi tro and in vivo transcription of DNA sequences encoding the antisense RNA molecule.
  • DNA sequences may be incor ⁇ porated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters.
  • antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be. introduced stably into cell lines.
  • DNA molecules may be introduced as a means of increasing intracellular stabil- ity and half-life. Possible modifications include but are not limited to the addition of flanking sequences of ribo- or deoxy- nucleotides to the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the oligode- oxyribonucleotide backbone.
  • the particular antagonist compound, antisense or ribozyme molecule or IR-95 protein of the present inven ⁇ tion that affects the disorder of interest can be admin- istered to a patient either by themselves, or in pharma ⁇ ceutical compositions where it is mixed with suitable carriers or excipient (s) .
  • IR-95 or antagonists thereof can routinely be prepared as therapeutic agent(s) by one of skill in the art using standard techniques and references which are well known in the art (see, for example, Remington ' s Pharmaceutical Sciences, 18th ed. , (A.R. Gennaro, Ed.), Mack Publishing Comp., Easton, PA, USA 18042 (1990), especially chapters 8 (Pharmaceutical Preparations and Their Manufacture) and 4 (Testing and Analysis) , thereof) .
  • Appropriate and optimum routes of administration can also be routinely determined by one of skill in the art.
  • the former include the oral, intravenous, intramuscular, subcutaneous, transdermal, in si tu and bucal routes of administration among others.
  • a therapeutically effective amount of a agent or agents such as these is administered.
  • a therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms or a prolongation of survival in a patient.
  • Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g. , for determin- ing the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population) .
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 50 /ED 50 .
  • Compounds which exhibit large therapeutic indices are preferred.
  • the data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose can be estimated ini- tially from cell culture assays.
  • a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 as deter ⁇ mined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of the cellular level and/or activity of IR-95) .
  • Such informa ⁇ tion can be used to more accurately determine useful doses in humans.
  • Levels in plasma may be measured, for example, by HPLC.
  • the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g. Fingl et al., in The Pharmacological Basis of Therapeutics, 1975, Ch. 1 p. 1) . It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity, or to organ dys ⁇ functions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity) .
  • the magnitude of an administrated dose in the management of the oncogenic disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veteri ⁇ nary medicine.
  • Suitable routes may include oral, rectal, trans- dermal, vaginal, transmucosal, or intestinal administra ⁇ tion; parenteral delivery, including intramuscular, sub- cutaneous, intramedullary injections, as well as intra- thecal, direct intraventricular, intravenous, intra- peritoneal, intranasal, or intraocular injections, just to name a few.
  • the agents of the invention may be formulated in aqueous solutions, preferably in physio ⁇ logically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
  • aqueous solutions preferably in physio ⁇ logically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formula- tion. Such penetrants are generally known in the art.
  • compositions of the present invention in particular, those formulated as solutions, may be adminis ⁇ tered parenterally, such as by intravenous injection.
  • the compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration.
  • Such carriers enable the compounds of the invention to be formulated as tab ⁇ lets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • Agents intended to be administered intracellularly may be administered using techniques well known to those of ordinary skill in the art. For example, such agents may be encapsulated into liposomes, then administered as described above. Liposomes are spherical lipid bilayers with aqueous interiors. All molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior. The liposomal contents are both protected from the external microenvi- ronment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. Addi- tionally, due to their hydrophobicity, small organic molecules may be directly administered intracellularly.
  • compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
  • these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • the preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.
  • compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • compositions for parenteral admin- istration include aqueous solutions of the active com ⁇ pounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspen ⁇ sions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • compositions for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellu ⁇ lose, and/or polyvinylpyrrolidone (PVP) .
  • PVP polyvinylpyrrolidone
  • disintegrating agents may be added, such as the cross- linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combina ⁇ tions of active compound doses.
  • compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubri ⁇ cants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added.
  • the nucleic acid sequence encoding IR-95 can be administered prophylactically, or to patients having a disorder listed above, e . g. , by exogenous delivery of the nucleic acid sequence encoding IR-95 as naked DNA, DNA associated with specific carriers, or in a nucleic acid expression vector to a desired tissue by means of an appropriate delivery vehicle, e . g. , a liposome, by use of iontophoresis, electroporation and other pharmacologically approved methods of delivery.
  • Routes of administration may include intramuscular, intravenous, aerosol, oral (tablet or pill form) , topical, systemic, ocular, as a suppository, intraperitoneal and/or intrathecal.
  • Some methods of delivery include: a. encapsulation in liposomes, b. transduction by retroviral vectors, c. localization to nuclear compartment utilizing nuclear targeting site found on most nuclear proteins, d. transfection of cells ex vivo with subsequent reimplantation or administration of the trans ⁇ fected cells, e. a DNA transporter system.
  • a IR-95 nucleic acid sequence may be administered utilizing an ex vivo approach whereby cells are removed from an animal, transduced with the IR-95 nucleic acid sequence and reimplanted into the animal.
  • the liver can be accessed by an ex vivo approach by removing hepatocytes from an animal, transducing the hepatocytes in vi tro with the IR-95 nucleic acid sequence and reimplanting them into the animal (e. g. , as described for rabbits by Chowdhury et al, Science 254: 1802-1805, 1991, or in humans by Wilson, Hum. Gene Ther. 3: 179-222, 1992) incorporated herein by reference.
  • IR-95 nucleic acid sequence into a cell
  • direct naked DNA uptake e.g., Wolff et al., Science 247: 1465-1468, 1990
  • receptor-mediated DNA uptake e. g. , using DNA coupled to asialoorosomucoid which is taken up by the asialoglycoprotein receptor in the liver
  • liposome-mediated delivery e . g. , Kaneda et al., Expt. Cell Res.
  • the IR-95 or nucleic acid encoding IR-95 may also be administered via an implanted device that provides a support for growing cells.
  • the cells may remain in the implanted device and still provide the useful and therapeutic agents of the present invention.
  • Retroviral vectors can be used for transducing the IR-95 vector into liver cells or muscle.
  • the advantage of retrovirus as a delivery system is the ability of the virus to integrate into the host cell chromosomes (reviewed by A.D. Miller, Hum. Gene Ther. 1: 5-14, 1990).
  • the IR-95 vector can be delivered by retroviral-mediated gene transfer, a two- component system consisting of the packaging cell and the viral vector.
  • the IR-95 nucleic acid sequence can be inserted into the retroviral vector by molecular cloning (e.g., as described by Wilson, Hum. Gene Ther. 3: 179-222, 1992) .
  • the virus particle assembled by the producer cell line i.e., a packaging cell line containing the IR-95- containing retroviral vector
  • a target organ or tissue such as liver cells in vivo (following partial hepatectomy because only dividing cells take up retroviral vectors) , isolated hepatocytes in vi tro or skeletal muscle in vivo.
  • the virus particle will bind to the cell and deliver the IR-95 nucleic acid sequence which is integrated into the host genome and result in stable long-term expression of the IR-95.
  • retroviral vectors Two major limitations to the use of retroviral vectors are the restricted host-cell range and the inability to obtain high-titer virus. These limitations have been overcome by Burns et al., Proc. Natl. Acad. Sci. USA 90: 8033-8037, 1993. They replaced the retroviral envelope glycoprotein with the G glycoprotein of vesicular stomatitis virus. Such vectors can be produced in high titer (>10 9 colony-forming units/ml) and can infect diverse cell types. Partial hepatectomy may not be necessary for liver expression using such vectors.
  • the nucleic acid sequence encoding IR-95 can be delivered by using this or a similarly designed vector in vivo by intravenous administration. Another viral vector delivery system that will be used is the adenovirus system. The IR-95 nucleic acid sequence can be used to replace the El region of the adenovirus using the method described by Graham and Prevec
  • IR-95 nucleic acid sequence/adenovirus can be injected intravenously, intramuscularly, intraportally or intra-arterially (hepatic artery) .
  • adenovirus- mediated expression vectors generally direct the transient expression of the therapeutic gene. Improvements and refinements in vector structure and design may lead to diminished immunogenicity and allow the vector to be administered repeatedly. Other modifications may result in the ability of the IR-95 nucleic acid sequence to be integrated in the host chromosomes allowing for stable expression.
  • viral vector delivery systems as are known in the art will also be used for the targeted transfer of the IR-95 nucleic acid sequence.
  • IR-95 By “functional derivative” is meant a “chemical derivative,” “fragment,” “variant,” “chimera,” or “hybrid” of IR-95, which terms are defined below.
  • a functional derivative retains at least a portion of the function of the protein, for example reactivity with an antibody spe ⁇ cific for IR-95, which permits its utility in accordance with the present invention.
  • a "chemical derivative" of IR-95 contains additional chemical moieties not normally a part of the protein. Covalent modifications of the protein or peptides are included within the scope of this invention. Such modifi ⁇ cations may be introduced into the molecule by reacting targeted amino acid residues of the peptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues, as described below.
  • Cysteinyl residues most commonly are reacted with alpha-haloacetates (and corresponding amines) , such as chloroacetic acid or chloroacetamide, to give carboxy- methyl or carboxyamidomethyl derivatives. Cysteinyl residues also are derivatized by reaction with bromotri- fluoroacetone, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-l,3-diazole.
  • Histidyl residues are derivatized by reaction with diethylprocarbonate at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain.
  • Para- bromophenacyl bromide also is useful; the reaction is preferably performed in 0.1 M sodium cacodylate at pH 6.0.
  • Lysinyl and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. Deriva- tization with these agents has the effect or reversing the charge of the lysinyl residues.
  • Other suitable reagents for derivatizing primary amine containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitro- benzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.
  • Arginyl residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high pK a of the guanidine functional group. Further- more, these reagents may react with the groups of lysine as well as the arginine alpha-amino group.
  • Tyrosyl residues are well-known targets of modifi ⁇ cation for introduction of spectral labels by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidizol and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.
  • Carboxyl side groups are selectively modified by reaction carbodiimide (R' -N-C-N- R' ) such as l-cyclohexyl-3- (2-morpholinyl(4-ethyl) carbo ⁇ diimide or l-ethyl-3- (4-azonia-4,4-dimethylpentyl) carbo ⁇ diimide.
  • carbodiimide R' -N-C-N- R'
  • aspartyl and glutamyl residue are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.
  • Glutaminyl and asparaginyl residues are frequently deamidated to the corresponding glutamyl and aspartyl residues.
  • these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention.
  • Derivatization with bifunctional agents is useful, for example, for cross-linking IR-95 to a water-insoluble support matrix or to other macromolecular carriers.
  • cross-linking agents include, for example, 1, 1-bis (diazoacetyl) -2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3' -dithiobis- (succinimidylpropionate) , and bifunctional maleimides such as bis-N-maleimido-1,8-octane.
  • Derivatizing agents such as methyl-3- [p-azidophenyl) dithiolpropioimidate yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light.
  • reactive water-insoluble matrices such as cyanogen bro ⁇ mide-activated carbohydrates and the reactive substrates described in U.S. Patent Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization.
  • Such derivatized moieties may improve the stability, solubility, absorption, biological half life, and the like.
  • the moieties may alternatively eliminate or attenuate any undesirable side effect of IR-95 and the like.
  • Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences, 18th ed. , Mack Publishing Co., Easton, PA (1990) .
  • fragment is used to indicate a polypeptide derived from the amino acid sequence of the protein IR-95 having a length less than the full-length polypeptide from which it has been derived.
  • a fragment may, for example, be produced by proteolytic cleavage of the full- length protein.
  • the fragment is obtained recombinantly by appropriately modifying the DNA sequence encoding the proteins to delete one or more amino acids at one or more sites of the C-terminus, N-terminus, and/or within the native sequence.
  • Fragments of a protein when present in an immune complex resembling a naturally occur ⁇ ring immune complex, are useful for screening for com ⁇ pounds that act to modulate immune responses, as described below.
  • fragments when present in a complex may retain one or more characterizing portions of the native complex. Examples of such retained characteristics include: substrate specificity; inter ⁇ action with other molecules in the intact cell; regulatory functions; or binding with an antibody specific for the native complex, or an epitope thereof.
  • Another functional derivative intended to be within the scope of the present invention is a IR-95 comprising at least one "variant" polypeptide which either lack one or more amino acids or contain additional or substituted amino acids relative to the native polypeptide.
  • the variant may be derived from a naturally occurring IR-95 by appropriately modifying the protein DNA coding sequence to add, remove, and/or to modify codons for one or more amino acids at one or more sites of the C-terminus, N-terminus, and/or within the native sequence. It is understood that such variants having added, substituted and/or additional amino acids retain one or more characterizing portions of the native IR-95, as described above.
  • a functional derivative of IR-95 comprising proteins with deleted, inserted and/or substituted amino acid resi- dues may be prepared using standard techniques well-known to those of ordinary skill in the art.
  • the modified components of the functional derivatives may be produced using site-directed mutagenesis techniques (as exemplified by Adelman et al., 1983, DNA 2:183) wherein nucleotides in the DNA coding the sequence are modified such that a modified coding sequence is modified, and thereafter expressing this recombinant DNA in a prokary- otic or eukaryotic host cell, using techniques such as those described above.
  • IR-95 with amino acid deletions, insertions and/ or substitutions may be conveniently prepared by direct chemical synthesis, using methods well-known in the art.
  • the functional derivatives of IR-95 typically exhibit the same qualitative biological activity as the native IR-95. Examples
  • RPMI medium was supplemented with 10% heat- inactivated fetal calf serum and glutamine. This formu ⁇ lation will be abbreviated as RPMI+FCS.
  • Minimal essential medium was supplemented with 10% heat-inactivated fetal calf serum and glutamine. This formulation will be abbreviated as MEM+FCS.
  • HT-2 cells an IL-2-dependent murine cell line, were passaged every 2 days in RPMI+FCS supple- mented with 40 U/ml recombinant murine IL-2 (Genzyme) .
  • 7TD1 cells an IL-6-dependent murine B-cell hybridoma
  • RPMI+FCS supplemented with 50 U/ml recombinant murine IL-6 (Genzyme) .
  • A375.S2 cells an IL-1-sensitive human melanoma line, were passaged twice weekly in MEM+FCS.
  • A375.S2 cells grow as adherent cells, and their growth is inhibited by human IL-1.
  • U373 is a human glioblastoma cell line which produces natural IR-95; these cells were passaged twice weekly in MEM+FCS supple ⁇ mented with non-essential amino acids and sodium pyruvate.
  • BT2A4 cells were derived from NIH.3T3 cells by transfec ⁇ tion with an expression vector containing the full length cDNA encoding human IR-95, followed by methotrexate ampli ⁇ fication to select a clone which expressed high levels of recombinant IR-95 (Ullrich et al. , J. Biol . Chem. 269:18401-18407, 1994) .
  • THP-1 is a human monocytic leukemia cell line, which was passaged twice weekly in RPMI+FCS. All cell lines were obtained from the American Type Culture Collection.
  • BT2A4 cells were seeded into cell factories in DMEM + 5% FCS + glutamine. When the cells reached confluence, the FCS concentration was gradually reduced to 0.5%.
  • Conditioned medium (CM) was collected every two days, filter- sterilized, and stored at 4°C. CM was concentrated approximately 20-fold with a 20K cut-off cross filtration unit (Sartorius) , followed by precipitation with 45% saturated ammonium sulfate.
  • ammonium sulfate cut was passed over an affinity column consisting of a purified monoclonal antibody specific for human IR-95 (Iacobelli et al., Breast Cancer Research and Treatment 11:19-30, 1993; Ullrich et al. , J. Biol . Chem. 269:18401-18407, 1994) covalently coupled to Tresyl-activated agarose (Schleicher & Schuell) . After extensive washing with PBS to remove non-bound material, the bound material was eluted with IM ethanolamine (prep 1) or 3M MgCl 2 (prep 2) .
  • prep 1 IM ethanolamine
  • prep 2 3M MgCl 2
  • Peripheral blood mononuclear cells Blood was obtained from apparently healthy donors following informed consent. Peripheral blood mononuclear cells were isolated from the buffy coats by density gradient centrifugation through Histopaque (Sigma) . PBMC were washed extensively with RPMI+FCS. Cells were adjusted to the appropriate concentration and either frozen in 90% FCS + 10% DMSO, or used fresh. Frozen cells were thawed rapidly and washed twice before use. Viability was determined by trypan blue exclusion. Recovery of viable cells from liquid nitrogen storage generally ranged from 50% to 95% of input cells.
  • T-cell enrichment from PBMC Nylon wool-enriched T- cells were prepared essentially as described (Hathcock, 3.2.1 through 3.2.4 in Current Protocols in Immunology, Coligan et al. , eds. , Wiley Interscience (New York 1994)) . Briefly, PBMC were resuspended in RPMI + 20% FCS and applied to nylon wool columns which had been washed and equilibrated in the same medium. The columns were incu ⁇ bated at 37°C for one hour. Non-adherent (T-cell- enriched) cells were eluted by slowly washing the columns with warm RPMI + 20% FCS.
  • PBMC enriched for CD3+ and CD14+ cells using the MiniMACS Separation System (Miltenyi Biotec) , according to the manufacturer's instructions. Briefly, ali uots of 10 7 PBMC were stained with phycoerythrin-conjugated monoclonal antibodies to CD3 or CD14 (Leinco Technologies) for 15 minutes on ice.
  • ConA costimulation assay PBMC (or enriched fractions thereof) were resuspended in RPMI+FCS, and plated in 24- well plates (4xl0 6 /well unfractionated PBMC, an equivalent cell dose of fractionated PBMC) , or in 96-well flat-bottom plates (2xlO s /well PBMC) .
  • RPMI+FCS was added to control wells, and various combinations of ConA (Sigma catalog # C-5275) and IR-95 diluted in RPMI+FCS were added to experi ⁇ mental wells, as indicated in the figure legends. Cultures were incubated at 37°C for 48 hours unless otherwise noted. Supernatants were collected from indi ⁇ vidual wells, clarified by centrifugation, and frozen at -80°C until assayed for cytokine content.
  • Cytokine bioassays Samples and recombinant cytokine controls were serially diluted in 96-well flat bottom plates in a volume of 50 ⁇ l/well. The appropriate indi ⁇ cator cells were then added in 50 ⁇ l/well: HT-2, 10 /well for IL-2; 7TD1, 2xl0 3 /well for IL-6; A375.S2, 10 /well for
  • THP-1 cells a human monocytic cell line that possesses accessory function, were used to examine the effect of IR-95 on expression of adhesion molecules.
  • Cells were plated in 24-well plates at 4xl0 5 /well, in the presence or absence of purified IR-95 at various doses. Following an overnight incubation at 37°C, the cells were harvested and washed three times prior to staining with fluorochrome- labelled monoclonal antibodies to human cell surface antigens.
  • THP-1 cells were cultured overnight with or without IR-95, then harvested and washed. The cells were fixed in formalin or treated with mitomycin C prior to being used in a functional assay.
  • CD3+ cells were purified from PBMC by magnetic separation, as described above. THP-1 cells ( ⁇ 3xl0 /well) and CD3+ cells
  • Example 1 Increased IL-2 secretion by PBMC in response to ConA and IR-95-containing conditioned medium: Effect of IR-95 containing conditioned medium on the PBMC response to ConA was studied.
  • Conditioned media were collected from U373 (a human glioblastoma which naturally produces IR-95) , BT2A4 (IR-95-negative parental cells) , and NIH.3T3 cultures three days after passage. The CM were centrifuged and passed through 0.2 ⁇ M filters to remove cell debris.
  • PBMC Freshly-isolated PBMC (2xl0 6 /well in 24-well plates in a final volume of 1.0 ml) were cul ⁇ tured with doses of ConA up to 2.5 ⁇ g/ml, with or without CM (25% v/v final concentration) . After 48 hours, super ⁇ natants were harvested and assayed for IL-2 activity. IL-2 secretion was minimal at the doses of ConA used. However, the addition of CM from BT2A4 or U373 cells enhanced IL-2 secretion 2- to 5-fold in response to these suboptimal doses of the T-cell mitogen, while CM from the non-producing NIH.3T3 cells had no effect. CM alone did not induce IL-2 production by PBMC, suggesting that the increased IL-2 levels seen in the ConA + CM wells were due to a costimulation effect.
  • Example 2 Effect of purified recombinant IR-95 on lymphokine production by PBMC: The results described herein demonstrated that IR-95- containing CM could augment the PBMC response to ConA, but it was not clear whether this effect was due to IR-95 itself or some other component of CM. Therefore, recombi ⁇ nant IR-95 affinity-purified from BT2A4 CM was assayed in a similar fashion and the effect of purified IR-95 on lymphokine secretion by human PBMC was studied.
  • PBMC peripheral blood mononuclear cells
  • PBMC peripheral blood mononuclear cells
  • AP affinity-purified
  • GP gel- purified
  • supernatants were harvested and assayed for IL-1 and IL-6.
  • IL-1 and IL-6 were produced by the ConA-stimulated PBMC, and the levels of each cytokine were higher in cultures which had been costimulated with ConA and IR-95.
  • Example 3 Response of nylon wool-enriched T-cells to costimulation with ConA and IR-95:
  • IR-95 increased production of the accessory cell-derived cyto ⁇ kines IL-1 and IL-6, and of the T-cell-derived cytokine IL-2. Since these experiments were conducted with unfractionated PBMC populations, it was not possible to determine which cell type was the direct target of IR-95. Therefore, PBMC were passed over nylon wool columns to deplete B-cells, macrophages, and other accessory cells and the response of nylon wool-enriched T-cells to costimulation with ConA and IR-95 was studied. The nonad- herent cells, enriched for T-cells and NK cells, were then examined in the ConA costimulation assay described above; unfractionated PBMC were assayed in parallel.
  • Cultures consisted of 2xl0 6 unfractionated PBMC/well, or the nylon wool-nonadherent cells collected from an equivalent number of PBMC. One-half of the cells were then passed over nylon wool columns to deplete B-cells and accessory cells. The nonadherent cells were harvested, washed, and resus- pend to the original volume. Nylon wool-nonadherent cells or unfractionated cells were plated along with ConA IR-95 as indicated. ConA was added at 2.5 ⁇ g/ml, and IR-95 was added at 2 and 10 ⁇ g/ml. Supernatants were collected after 48 hours and assayed for cytokine bioactivity.
  • the T-cell-enriched population did not produce IL-2 in response to ConA, as expected, since ConA is an acces ⁇ sory cell-dependent mitogen.
  • ConA is an acces ⁇ sory cell-dependent mitogen.
  • the addition of IR-95 to the T-cell population did not restore the ability of these cells to make IL-2 in response to mitogenic stimulation.
  • the unfractionated PBMC did produce IL-2 when stimulated with ConA, and the level of IL-2 produced was higher when IR-95 was added to the cultures.
  • IL-6 was not produced by the enriched T-cell popula ⁇ tion, except in wells which contained both ConA and the highest dose of IR-95; this may represent contaminating accessory cells in the nylon wool nonadherent population, or IL-6 production by T-cells.
  • the unfrac ⁇ tionated PBMC produced IL-6 in the absence of ConA, and this response was increased by the addition of low doses of IR-95.
  • the ConA-independent production of IL-6 in response to IR-95 had been observed before, as described above.
  • Example 4 Production of IL-6 by CD14-enriched cells stimulated with IR-95 alone: IL-1 and IL-6 production by fractionated PBMC stimu ⁇ lated with IR-95 was studied.
  • PBMC were enriched for CD3+ and CD14+ cells by immunomagnetic sorting.
  • CD14-enriched fractions and unseparated PBMC were cultured with ConA + IR-95 for 48 hours. Supernatants were assayed for IL-1 and IL-6 bioactivity.
  • CD3-enriched fractions did not produce detectable levels of either IL-1 or IL-6.
  • T-cells The failure of nylon wool-enriched T-cells to respond to IR-95, and the ability of PBMC to produce IL-1 and IL-6 in response to IR-95 alone, suggested that the immediate target of IR-95 activity was accessory cells rather than T-cells.
  • PBMC were enriched for cells expressing CD3 (T-cells) and CD14 (monocytes/ macrophages) . These enriched fractions, as well as unseparated PBMC, were cultured with ConA + IR-95 for 48 hours, and supernatants were assayed for IL-1 and IL-6.
  • accessory cells In addition to secreting soluble cytokines such as IL-1 and IL-6, accessory cells also provide costimulatory signals to T-cells via adhesion molecules such as ICAM-1.
  • adhesion molecules such as ICAM-1.
  • ICAM-1 expression and accessory function of THP-1 cells pulsed with IR-95 was studied. THP-1 cells were cultured with and without involved IR-95 overnight, then stained with fluorochrome-labelled antibodies to various cell surface molecules. Cells were then harvested, washed, and analyzed for ICAM-1 expression by flow cytometry, and for accessory function by their ability to restore ConA responsiveness to purified CD3+ cells.
  • a fluorescence histogram of ICAM-1 expression was obtained, detected by staining the cells with PE-labelled anti-CD54 (Becton Dickinson) , followed by analysis on a BD FACScan using LYSIS II software.
  • 3 H-thymidine incorporation by ConA- stimulated CD3+ cells cocultured for 48 hours with THP-1 cells that had been previously pulsed overnight with and without IR-95 was measured.
  • ICAM-1 appeared to be influenced by IR-95.
  • ICAM-1 expression was increased up to 4-fold in 24 hours, while other important adhesion molecules, including B7 and LFA- 1, were not affected.
  • THP-1 cells Due to the importance of ICAM-1 and other adhesion molecules in T-cell costimulation, we investigated whether the IR-95-induced upregulation of ICAM-1 expression resulted in a functional change in the THP-1 cells. Following an overnight culture in the presence or absence of IR-95, THP-1 cells were harvested and washed, then cocultured with purified CD3+ PBMC and various doses of ConA for 48 hours. Proliferation of the CD3+ cells was measured as described. THP-1 cells possess endogeneous accessory function, demonstrated by their ability to support ConA-induced T- cell activation, and this function is apparently increased following culture with IR-95.
  • Example 6 The effect of IR-95 on cytokine production in peripheral blood lymphocytes:
  • IR-95 prepara ⁇ tion PS-1 and preparation Mg-1
  • lymphokine secretion by human peripheral blood lymphocytes was studied.
  • Peripheral blood lymphocytes were isolated by Ficoll gradient centrifugation of blood obtained from healthy volunteers.
  • the PBL (2xl0 6 cells/well in 24 well plates in a final volume of 1 ml) were cultured with various doses of Concanavalin A (ConA, potent T-cell mitogen) , and puri ⁇ fied IR-95, either separately or in combination.
  • Concanavalin A ConA, potent T-cell mitogen
  • cytokine content Unless otherwise indicated supernatants from the PBL cultures were harvested after 48 hours and stored at -80°C until analyzed for cytokine content.
  • the cytokines measured were IL-1, IL-2, and IL-6.
  • IL-1 and IL-6 are primarily derived from macrophages and other accessory cells and are vital in achieving full activation of T-cells. 11-2 is produced by activated T-helper cells.
  • IL-6 Samples and controls were incubated with the IL-6-dependent cell line 7TD1 for 4 days, then processed as described in the IL-2 assay.
  • IL-1 Samples and controls were incubated with IL-1- sensitive cell line A375.52 for 3 days.
  • IR-95 preparation PS-1 increased the production of the T-cell cytokine IL-2.
  • This response was dose dependent with respect to both ConA and IR-95, suggesting that the mitogen and IR-95 were acting in a synergistic manner to achieve an enhanced T- cell response.
  • IL-6 secretion was enhanced in response to IR-95 alone, without the addition of the T-cell mitogen ConA, suggesting that the effect of IR-95 is on accessory cell, and not directly on the T-cell. Production of IL-1 was also enhanced by the addition of IR-95 to the cultures.
  • IL-6 in the PBL supernatants.
  • ConA at a dose of 1.25 ug/ml does not achieve T-cell acti ⁇ vation as determined by the production of IL-2.
  • a significant T-cell activation can be achieved in the presence of 1.25 ug/ml ConA when IR-95 is also present at a dose of 20 ug/ml.
  • IR-95 increases the production of IL-1 and IL-6 by human PBL, and acts synergistically with ConA to increase the produc ⁇ tion of IL-2.
  • Example 7 The effect of IR-95 on tumor growth in nude mice.
  • the human IR-95 cDNA was subcloned into the retro ⁇ viral pLXSN vector (Miller, A.D. and Rosman, G.J., Biotechnique ⁇ 7 , 980-992 (1989) ) .
  • the latter plasmid was transfected into the helper virus-free packaging cell line PA 317 by calcium phosphate precipitation (Chen and Okayama, Mol . Cell . Biol . , 7:2745-2752, 1987) .
  • supernatants containing amphotropic virus were collected and used to infect GP86 secondary packaging cells in the presence of 8 ug/ml polybrene. Cells were then selected with G418 (1 mg/ml) and clones were isolated.
  • mice Female nude mice were divided into 4 groups of 4 individuals. Each individual in groups 1, 2, and 3 was implanted with clones of murine cell line 6378 which express human IR-95 (2 x 10 7 cells subcutaneously / mouse) . The animals in group 4 were implanted with 6378 cells transfected with the control expression vector. The tumor volume in each mouse was measured twice a week and the tumor growth curve determined. Twenty-three days post implantation, the tumor volume in mice implanted with cells expressing IR-95 was reduced by 40% (group 1) , and 70% (groups 2 and 3) as compared to the control.
  • Murine 6378 cells (derived from mouse mammary gland carcinoma) that do not express IR-95 were infected 4 times, about 4 h each time, with 1 ml viral supernatant
  • mice Female nude mice, 4 to 5 weeks old, were divided into 4 groups of 4 individuals. Each individual in groups 1, 2 and 3 was subcutaneously implanted with one of the high expression clones of murine 6378 cells (2 x IO 7 cells / mouse) . The animals in group 4 were implanted with 6378 cells infected with the control expression vector. Tumor volume was measured twice a week and the tumor growth curve determined. Results
  • Example 8 Correlation Between IR-95 Expression and Tumor Formation.
  • IR-95 as a stimulator of natural killer (NK) cell acti ⁇ vity suggested that this protein represents a molecular alarm signal for the cellular immune defense system against cancer cells and possibly virus infections 2 .
  • NK natural killer
  • a panel of cell lines derived from different tumor types was characterized with respect to IR-95 expression and their ability to form solid tumors in nude mice.
  • Table 1 shows that about 90% of the cell lines that displayed either no detectable or low levels of IR-95 expression formed tumors 10 to 15 days after subcutaneous implantation of 2 x IO 6 cells into nude mice, over 60% of the lines that expressed comparatively high levels of IR- 95 were not tumorigenic under identical experimental conditions. Mice inoculated with these cells remained tumor-free for at least six weeks. This effect was independent of the tissue origin and the species from which the original tumor was derived. These observations suggested that high level IR-95 expression by tumor cells suppressed tumor formation in nude mice, which, despite their lack of T cells, still possess functional macro- phages and NK cells, primary mediators of cell-mediated immunity.
  • IR-95 For further investigation of the role of IR-95 in tumor suppression, we employed a replication-defective retrovirus containing cDNA coding for human IR-95 under the transcriptional control of mouse sarcoma virus 3' long terminal repeat 9 for the modulation of IR-95 expression on several cancer cell lines, MM5 and B-29, were infected with recombinant LXSN-IR-95 virus or the parental LXSN virus as a control. While neither cell line had detect ⁇ able endogenous mRNA or IR-95 protein, high levels of secreted IR-95 were detected in the conditioned media after infection with the LXSN-IR-95 virus at a multipli- city of infection (MOD of 5.
  • MOD multipli- city of infection
  • MM5 and B-29 cells For MM5 and B-29 cells, clonal (MM5/90-1, MM5/90-2, B-29/90-1, B-29/90-2) as well as polyclonal (B-29/90P) IR-95-expressing lines were established after LXSN-IR-95 virus infection by selection for neomycin resistance. No induction of IR-95 expression was detected for parental LXSN virus-infected and subsequently G418-selected cells.
  • IR-95 protein was produced by retrovirus-infected tumor cells. MM5 and B-29 cells (ATCC, CRL 6444 and CRL 6325, respectively) were infected with the ecotropic retrovirus LXSN-IR-95 or the control virus LXSN. 80% confluent cells seeded in 6-cm dishes were labeled with [ 35 S]methionine in 0.1% dialysed FBS. Since IR-95 is secreted into the medium, the conditioned media of the labeled cells was analyzed for the presence of IR-95 protein by immunoprecipitation with the monoclonal antibody 19B5, SDS-polyacrylamide gel electrophoresis, and autoradiography.
  • RESULTS Generation of the recombinant retrovirus.
  • the IR-95 coding sequence was isolated from a Bluescript ksll vector, containing the full-length IR-95 cDNA 2 , as a EcoRV/XhoI restriction fragment and ligated into the retroviral vector pLXSN 9 , which was cut with Hpal and Xhol.
  • the helper virus-free packaging cell line PA317 20 was transfected with pLXSN-IR-95.
  • the low titer amphotropic viruses produced were used to infect GP+E-86 secondary packaging cells 21 .
  • the GP+E-86 producer clones were obtained after G418 selection.
  • Retrovirus-mediated gene transfer was performed as follows: Mouse mammary carcinoma cell lines were seeded at a density of 10 s cells per 6 cm dish. Cells were incubated with retrovirus-containing culture supernatant from GP+E-86 producer line clones for four hours in the presence of polybrene (4 ⁇ /ml; Aldrich) and at a MOI of 5. The infection cycle was repeated up to four time in order to achieve high IR-95 protein levels. After G418 selec ⁇ tion, clones and/or polyclonal populations of cells were isolated.
  • MM5/90-1, MM5/90-2, B-29/90-1, and B-29/90-2 are clonal lines, and B-29/90p is a polyclonal line of B-29 cells infected with LXSN-IR-95.
  • MM5/LXSN and B-29/LXSN are polyclonal kines of MM5 and B-29 cells infected with the control virus LXSN.
  • mice subcutaneously injected 2 x IO 6 cells of the clonal and polyclonal lines above the right hind legs of nude mice.
  • LXSN virus the same number of cells infected with LXSN virus only were implanted into the animals of the control group.
  • the growth of developing tumors was subsequently measured at regular intervals.
  • mice implanted with LXSN control virus-infected MM% or B-29 cells developed tumors, which increased in volume at an exponential rate (Fig. la . b) .
  • mice For each of the experimental groups eight mice were implanted with LXSN or LXSN-IR-95 virus-infected B-29 or MM5 cells, respectively. All animals in the control groups, together with six animals with LXSN-IR-95 virus- infected B-29 or MM5 cells, were sacrificed when the tumors of the control animals reached a volume of 2,500 mm 3 .
  • LXSN-IR-95 virus-infected cells two animals were kept or further surveillance of tumor development. The two mice implanted with B-29/90-1 cells ectopically expressing high levels of human IR-95 remained tumor-free for over three months. While one of these subsequently developed a slow growing tumor, the two experimental animals implanted with MM5/90-1 and MM5/90-2 cells remained tumor-free for over four months after cell implantation.
  • Example 12 In Vivo Tumor Inhibition By Systemic
  • ICAM-1 induction in vi tro by purified IR- 95 protein. While the expression of ICAM-1 and VCAM-1 by vascular endothelium, ICAM-1 expression is low but can be markedly induced by cytokines such as interleukin-1 (IL-1) tumor necrosis factor (TNF) , and interferon- ⁇ (IFN- ⁇ ) , and VCAM- 1 is not expressed in resting endothelium, but may be induced by IL-1, IL-4, or TNF 14 ' 15 . We observed induction of ICAM-1 and VCAM-1 in tumor endothelium by elevated local IR-95 concentrations.
  • IL-1 interleukin-1
  • TNF tumor necrosis factor
  • IFN- ⁇ interferon- ⁇
  • IR-95 This may be mediated directly by IR-95 or through cytokines secreted by accessory cells upon exposure to IR-95. Nevertheless, the increase of ICAM-1 and VCAM-1 expression could be a first step in IR- 95 action, which would allow the margination of leukocytes on the vessel wall and migration into the tissue, via interaction of these cell adhesion proteins with their respective ligands, LFA-1 and VLA-4.
  • Tumors were resected from animals which had been implanted with B-29/IR-95 cells or with control-infected cells. Sections were immunohistochemically stained with a mono ⁇ clonal anti-IR-95 antibody or with monoclonal antibodies directed against VACAM an dICAM-1. IR-95 expression in IR-95-secreting tumors (B-29/90-1 cells) , was measured, but at different magnifications. Tumor was resected from the control group, stained with anti-IR-95 antibodies; no positive staining could be detected.
  • IR-95-secretin tumors stained with anti-ICAM-1 antibodies were observed at magnifications of 4 x, 63 x and 40 x.
  • METHODS After sacrificing the animals, tumors were resected and embedded in tissue-tek (Miles) and frozen in liquid nitrogen. 5 urn thick sections were cut with a cryo- stat (Leica) and used for immunohistochemical analysis.
  • the monoclonal mouse antibody 19B5 was used, and ICAM-1 and VCAM were detected using specific biotin labelled monoclonal antibodies (Pharminge, San Diego) .
  • Table 1 shows the correlation between IR-95 expres ⁇ sion and tumor formation in nude mice.
  • Cell lines derived from different tumor types were tested for their ability to grow as xenografts in nude mice.
  • the expression of IR-95 was determined with either Northern analysis and/or Western blotting. Unless designated otherwise, the cell lines are of human origin. METHODS: For each cell line tested, 2 x 10 s to 1 x IO 7 cells were subcutaneously implanted in nude mice above the right hind leg.
  • mice were observed for a period of at least six weeks.
  • IR-95 expression levels of the lines grown in tissue culture were determined by Norther analysis and/or immunoblotting, using specific monoclonal and-IR-95 antibodies. -: no detectable IR-95 expression; +++: high IR-95 expression levels.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de traitement de troubles par administration d'une dose thérapeutiquement efficace d'IR-95 à un patient nécessitant ce traitement. Les maladies troubles comprennent des cancers, des infections bactériennes et des infections virales. L'invention concerne également un procédé servant à supprimer une réaction immune par administration d'une dose thérapeutiquement efficace d'un antagoniste d'IR-95 à un organisme, tel que celui d'un patient atteint de troubles autoimmuns.
PCT/US1994/012701 1993-11-05 1994-11-04 Procede relatif a l'ir-95 WO1995012681A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU10498/95A AU1049895A (en) 1993-11-05 1994-11-04 Methods relating to ir-95
EP95901140A EP0725828A1 (fr) 1993-11-05 1994-11-04 Procede relatif a l'ir-95

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14728593A 1993-11-05 1993-11-05
US08/147,285 1993-11-05

Publications (1)

Publication Number Publication Date
WO1995012681A1 true WO1995012681A1 (fr) 1995-05-11

Family

ID=22520972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/012701 WO1995012681A1 (fr) 1993-11-05 1994-11-04 Procede relatif a l'ir-95

Country Status (4)

Country Link
EP (1) EP0725828A1 (fr)
AU (1) AU1049895A (fr)
CA (1) CA2175922A1 (fr)
WO (1) WO1995012681A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012050A1 (fr) * 1995-09-27 1997-04-03 The Rockefeller University Procede de transfert de genes vers le coeur a l'aide de vecteurs de virus adeno-associes
US7285540B2 (en) 1995-08-29 2007-10-23 Anges Mg, Inc. Medicament comprising HGF gene
WO2023064644A2 (fr) 2021-10-15 2023-04-20 Exelus Inc. Alkylation de paraffine catalysée par un acide solide avec des adsorbants de tamis moléculaire modifiés par des terres rares

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016180A2 (fr) * 1992-02-17 1993-08-19 Max Planck Gesellschaft Sequences genetiques pour un antigene 90k associe aux tumeurs (ir-95)
WO1993016181A1 (fr) * 1992-02-17 1993-08-19 New York University Antigene 90k associe aux tumeurs (ir-95)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016180A2 (fr) * 1992-02-17 1993-08-19 Max Planck Gesellschaft Sequences genetiques pour un antigene 90k associe aux tumeurs (ir-95)
WO1993016181A1 (fr) * 1992-02-17 1993-08-19 New York University Antigene 90k associe aux tumeurs (ir-95)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ULRICH A., ET AL.: "The Secreted Tumor-associated Antigen 90K is a Potent Immune Stimulator", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 269, no. 28, 15 July 1994 (1994-07-15), BALTIMORE, MD US, pages 18401 - 18407 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285540B2 (en) 1995-08-29 2007-10-23 Anges Mg, Inc. Medicament comprising HGF gene
WO1997012050A1 (fr) * 1995-09-27 1997-04-03 The Rockefeller University Procede de transfert de genes vers le coeur a l'aide de vecteurs de virus adeno-associes
WO2023064644A2 (fr) 2021-10-15 2023-04-20 Exelus Inc. Alkylation de paraffine catalysée par un acide solide avec des adsorbants de tamis moléculaire modifiés par des terres rares

Also Published As

Publication number Publication date
EP0725828A1 (fr) 1996-08-14
CA2175922A1 (fr) 1995-05-11
AU1049895A (en) 1995-05-23

Similar Documents

Publication Publication Date Title
Pol et al. Effects of interleukin-2 in immunostimulation and immunosuppression
KR100603075B1 (ko) Ｍｈｃ 클래스 ⅱ 리간드의 예방접종을 위한 항항원체로의이용과 ｌａｇ-3의 암 치료에의 이용
US8193309B2 (en) Compositions and methods for preventing or treating cancer
EP2186889B1 (fr) Peptide cdca1 et agent pharmaceutique le comprenant
JP5898260B2 (ja) 併用療法におけるｃｄ８３の使用
KR101661365B1 (ko) 단구로부터 수상 세포양 분화를 유도하여, 항암 면역 활성을 높이는 암의 치료 또는 예방을 위한 의약 조성물
CN110799206A (zh) 使用可溶性cd24治疗癌症疗法中免疫相关不良事件的方法
US20070286807A1 (en) Method Of Inducing Or Modulating Immune Response
US20100040636A1 (en) Manipulation of Regulatory T Cell and Dc Function By Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists
JP2006507240A (ja) 免疫機能の調節
JP2005515971A (ja) モジュレーター
KR102055847B1 (ko) 암 살해세포의 살해능을 증가시키는 암 치료용 재조합 단백질 및 이의 용도
Yamamoto et al. The activity of immunoregulatory T cells mediating active tolerance is potentiated in nonobese diabetic mice by an IL-4-based retroviral gene therapy
Akazawa et al. Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors
Zhang et al. C6 glioma cells retrovirally engineered to express IL-18 and Fas exert FasL-dependent cytotoxicity against glioma formation
WO1995012681A1 (fr) Procede relatif a l'ir-95
US6627200B1 (en) Utilization of CD 137 in order to promote the proliferation of peripheral monocytes
US6664232B1 (en) HLA-A2 restraint tumor antigen peptide originating in SART-1
CN107896494B (zh) 多肽组合物
EP3958887B1 (fr) Procédures médicales d'induction ou de récupération de la tolérance immunitaire
Zhao et al. The Collective Effect of MIP-3α and FL Promotes Dendritic Cell Function Within the Immune Microenvironment of Murine Liver Cancer
Elliott et al. Immunology: Paper alert
KR20220056822A (ko) 이종 면역세포에 대한 화학주성을 유도하는 형질전환된 면역세포
US20190240327A9 (en) Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
US20170198026A1 (en) Compositions And Methods For Treating Tumors And Immune Based Inflammatory Diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2175922

Country of ref document: CA

Ref document number: 1995901140

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995901140

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995901140

Country of ref document: EP